Madsen Melanie, Messenger Kristen, Papich Mark G
Am J Vet Res. 2019 Oct;80(10):957-962. doi: 10.2460/ajvr.80.10.957.
To determine the pharmacokinetics of levofloxacin following oral administration of a generic levofloxacin tablet and IV administration to dogs and whether the achieved plasma levofloxacin concentration would be sufficient to treat susceptible bacterial infections.
6 healthy adult Beagles.
Levofloxacin was administered orally as a generic 250-mg tablet (mean dose, 23.7 mg/kg) or IV as a solution (15 mg/kg) to each dog in a crossover study design, with treatments separated by a minimum 2-day washout period. Blood samples were collected at various points for measurement of plasma levofloxacin concentration via high-pressure liquid chromatography. Pharmacokinetic analysis was performed with compartmental modeling.
After oral administration of the levofloxacin tablet, mean (coefficient of variation) peak plasma concentration was 15.5 μg/mL (23.8%), mean elimination half-life was 5.84 hours (20.0%), and mean bioavailability was 104% (29.0%). After IV administration, mean elimination half-life (coefficient of variation) was 6.23 hours (14.7%), systemic clearance was 145.0 mL/kg/h (22.2%), and volume of distribution was 1.19 L/kg (17.1%).
In these dogs, levofloxacin was well absorbed when administered orally, and a dose of approximately 25 mg/kg was sufficient to reach pharmacokinetic-pharmacodynamic targets for treating infections with susceptible Enterobacteriaceae (ie, ≤ 0.5 μg/mL) or (ie, ≤ 1 μg/mL) according to clinical breakpoints established by the Clinical and Laboratory Standards Institute.
确定口服通用型左氧氟沙星片及静脉注射后左氧氟沙星在犬体内的药代动力学,以及所达到的血浆左氧氟沙星浓度是否足以治疗易感细菌感染。
6只健康成年比格犬。
在交叉研究设计中,给每只犬口服一片250毫克的通用型左氧氟沙星片(平均剂量,23.7毫克/千克)或静脉注射溶液(15毫克/千克),治疗间隔至少2天的洗脱期。在不同时间点采集血样,通过高压液相色谱法测量血浆左氧氟沙星浓度。采用房室模型进行药代动力学分析。
口服左氧氟沙星片后,平均(变异系数)血浆峰浓度为15.5微克/毫升(23.8%),平均消除半衰期为5.84小时(20.0%),平均生物利用度为104%(29.0%)。静脉注射后,平均消除半衰期(变异系数)为6.23小时(14.7%),全身清除率为145.0毫升/千克/小时(22.2%),分布容积为1.19升/千克(17.1%)。
在这些犬中,口服左氧氟沙星吸收良好,根据临床和实验室标准研究所制定的临床切点,约25毫克/千克的剂量足以达到治疗易感肠杆菌科感染(即≤0.5微克/毫升)或(即≤1微克/毫升)的药代动力学-药效学目标。